NCT06185400 2023-12-29RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Not yet recruiting108 enrolled